Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U7AA
|
|||
| Former ID |
DNC002324
|
|||
| Drug Name |
ISIS 109490
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Company |
Isis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | RANK messenger RNA (RANK mRNA) | Target Info | . | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| Osteoclast differentiation | ||||
| Prolactin signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| WikiPathways | RANKL/RANK Signaling Pathway | |||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | US patent application no. 6,171,860, Antisense inhibition of rank expression. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.